Skip to main content
Premium Trial:

Request an Annual Quote

Strong Words

In a sharply worded editorial, Holden Thorp, the editor-in-chief of the Science family of journals, asks US President Donald Trump to treat science with respect.

The editorial, the Washington Post notes, is "an unusually strong rebuke from the typically apolitical scientific community."

In it, Thorp notes that the Trump Administration has repeatedly sought to slash science and research budgets and that the President has expressed skepticism of vaccines in the past. He further writes that the administration has also sought to limit what public health officials say and has distorted what they have said. For instance, he writes that the administration has repeatedly said that the spread of SARS-CoV-2 in the US has been contained, when there is evidence it is spreading.

Now, when told that developing a vaccine for SARS-CoV-2 would take more than a year, President Trump asked pharmaceutical executives to speed that process up when that is not possible.

"You can't insult science when you don't like it and then suddenly insist on something that science can't give on demand," Thorp writes.

"If you want something, start treating science and its principles with respect," he adds.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.